 The purpose of this trial is to determine if patients with hematologic diseases who have a HLA 66 matched related donor and are not eligible for a standard myeloablative stem cell transplant will have less severe graft versus host disease GVHD, transplant related mortality, and less graft failure when treated with a non-myeloablative T-cell depleted stem cell transplant. 